Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0JFGYQ)
| ADC Name |
caxmotabart entudotin
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
LCB14-0110; FS-1502; IKS014; LCB-ADC
Click to Show/Hide
|
|||||
| Organization |
LCB (Originator);Fosun Pharma;Iksuda Therapeutics
|
|||||
| Drug Status |
Phase 3
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (HER2)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin F
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
β-glucuronide linker
|
Linker Info | ||||
| Conjugate Type |
Enzymatic Catalysis
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Disease Name | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
| Gastroesophageal junction adenocarcinoma | ||||
| Gastric cancer | ||||
| Colorectal cancer | ||||
| Lung cancer | ||||
| Breast cancer | ||||
| Unspecific solid tumor |
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
66.70
42.90 % |
|||
| Patients Enrolled |
Patients with HER2-expresssing advanced solid tumors who had failed prior standard of care therapies.
|
||||
| Administration Dosage |
FS-1502 was given IV once in 21-day or 28-day cycle at doses of 0.10-3.50 mg/kg.
|
||||
References